Dale W. Garsed

Dale W. Garsed

Auto-generated profile, based on publicly available information

Dale W. Garsed

Peter MacCallum Cancer Centre, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2015 in Nature
Verified
Journal Article
Closed access
PDF file
APAnn-Marie Patch
Ann-Marie Patch
ECElizabeth L Christie
Elizabeth L Christie
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
DGDale W. Garsed
Dale W. Garsed
JGJoshy George
Joshy George
DBDavid D. L. Bowtell
David D. L. Bowtell

1 November 2014 in Cancer Cell
Verified
Journal Article
Closed access
DGDale W. Garsed
Dale W. Garsed
OMOwen J. Marshall
Owen J. Marshall
VCVincent D.A. Corbin
Vincent D.A. Corbin
AHArthur Hsu
Arthur Hsu
LSLeon Di Stefano
Leon Di Stefano
DTDavid M. Thomas
David M. Thomas

1 December 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DGDale W. Garsed
Dale W. Garsed
APAhwan Pandey
Ahwan Pandey
SFSian Fereday
Sian Fereday
CKCatherine J. Kennedy
Catherine J. Kennedy
KTKazuaki Takahashi
Kazuaki Takahashi
DBDavid D. L. Bowtell
David D. L. Bowtell

31 January 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DGDale W Garsed
Dale W Garsed
KAKathryn Alsop
Kathryn Alsop
SFSian Fereday
Sian Fereday
CECatherine Emmanuel
Catherine Emmanuel
CKCatherine J Kennedy
Catherine J Kennedy
NGNadia Traficante, for the Australian Ovarian Cancer Study Group
Nadia Traficante, for the Australian Ovarian Cancer Study Group
Purpose: Women with epithelial ovarian cancer generally have a poor prognosis; however, a subset of patients has an unexpected dramatic and durable response to treatment. We sought to identify clinical, pathological, and molecular determinants of exceptional survival in women with high-grade serous cancer (HGSC), a disease associated with the majority of ovarian cancer deaths. Experimental Design: We evaluated the histories of 2,283 ovarian cancer patients and, after applying stringent clinical and pathological selection criteria, identified 96 with HGSC that represented significant outliers in terms of treatment response and overall survival. Patient samples were characterized immunohistochemically and by genome sequencing. Results: Different patterns of clinical response were seen: long progression-free survival (Long-PFS), multiple objective responses to chemotherapy (Multiple Responder), and/or greater than 10-year overall survival (Long-Term Survivors). Pathogenic germline and somatic mutations in genes involved in homologous recombination (HR) repair were enriched in all three groups relative to a population-based series. However, 29% of 10-year survivors lacked an identifiable HR pathway alteration, and tumors from these patients had increased Ki-67 staining. CD8+ tumor-infiltrating lymphocytes were more commonly present in Long-Term Survivors. RB1 loss was associated with long progression-free and overall survival. HR deficiency and RB1 loss were correlated, and co-occurrence was significantly associated with prolonged survival. Conclusions: There was diversity in the clinical trajectory of exceptional survivors associated with multiple molecular determinants of exceptional outcome in HGSC patients. Concurrent HR deficiency and RB1 loss were associated with favorable outcomes, suggesting that co-occurrence of specific mutations might mediate durable responses in such patients. Clin Cancer Res; 24(3); 569–80. ©2017 AACR. See related commentary by Peng and Mills, p. 508

27 February 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
NBNikki L. Burdett
Nikki L. Burdett
MWMadelynne O. Willis
Madelynne O. Willis
KAKathryn Alsop
Kathryn Alsop
AHAllison L. Hunt
Allison L. Hunt
APAhwan Pandey
Ahwan Pandey
ECElizabeth L Christie
Elizabeth L Christie

14 August 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
WAWalid J. Azar
Walid J. Azar
YLYing Lei
Ying Lei
TMTania Moujaber
Tania Moujaber
DGDale W. Garsed
Dale W. Garsed
FGfor The Australian Ovarian Cancer Study Group
for The Australian Ovarian Cancer Study Group
Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF, and NRAS. RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in NRAS and EIF1AX. Missense EIF1AX mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant NRAS and EIF1AX proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer. Cancer Res; 77(16); 4268–78. ©2017 AACR.